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Background-—Valvular interstitial cells (VICs) in the healthy aortic valve leaﬂet exhibit a quiescent phenotype, with <5% of VICs
exhibiting an activated phenotype. Yet, in vitro culture of VICs on tissue culture polystyrene surfaces in standard growth medium
results in rapid transformation to an activated phenotype in >90% of cells. The inability to preserve a healthy VIC phenotype during
in vitro studies has hampered the elucidation of mechanisms involved in calciﬁc aortic valve disease. This study describes the
generation of quiescent populations of porcine VICs in 2-dimensional in vitro culture and their utility in studying valve pathobiology.
Methods and Results-—Within 4 days of isolation from fresh porcine hearts, VICs cultured in standard growth conditions were
predominantly myoﬁbroblastic (activated VICs). This myoﬁbroblastic phenotype was partially reversed within 4 days, and fully
reversed within 9 days, following application of a combination of a ﬁbroblast media formulation with culture on collagen coatings.
Speciﬁcally, culture in this combination signiﬁcantly reduced several markers of VIC activation, including proliferation, apoptosis,
a-smooth muscle actin expression, and matrix production, relative to standard growth conditions. Moreover, VICs raised in a
ﬁbroblast media formulation with culture on collagen coatings exhibited dramatically increased sensitivity to treatment with
transforming growth factor b1, a known pathological stimulus, compared with VICs raised in either standard culture or medium
with a ﬁbroblast media formulation.
Conclusions-—The approach using a ﬁbroblast media formulation with culture on collagen coatings generates quiescent VICs that
more accurately mimic a healthy VIC population and thus has the potential to transform the study of the mechanisms of VIC
activation and dysfunction involved in the early stages of calciﬁc aortic valve disease. ( J Am Heart Assoc. 2017;6:e005041. DOI:
10.1161/JAHA.116.005041.)
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T he aortic heart valve is populated primarily by valvularinterstitial cells (VICs), a heterogeneous, multipotent1
cell population responsible for maintaining valve homeosta-
sis.2 In healthy leaﬂets, most VICs exhibit a quiescent (qVIC)
phenotype, but injury or stress can trigger their activation into
a myoﬁbroblastic (activated [aVIC]) phenotype.3 The aVICs are
proliferative and highly contractile and possess an increased
capacity to secrete and remodel the extracellular matrix
(ECM).4 On completion of the repair process, aVICs are
typically eliminated by apoptosis; however, in pathological
processes, VICs remain activated and are thought to play an
active role in the initiation and progression of valvular
disease.5–7
The ability to replicate VIC activation from a quiescent
state in vitro is critically important for studying molecular and
cellular features of aortic valve disease initiation and
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progression. However, although <5% of resident VICs in a
healthy aortic valve exhibit an aVIC phenotype,8 >90% of VICs
found in standard in vitro culture conditions are aVICs, as
these cells appear to undergo a rapid transformation to an
aVIC phenotype when cultured on tissue culture polystyrene
(TCPS) in growth medium.4,9 In addition, a microarray
comparison between freshly isolated versus cultured porcine
VICs revealed >4000 differentially expressed genes as early
as 6 days after the beginning of in vitro culture.10 The
dominance of the aVIC phenotype in in vitro cultures is likely
to signiﬁcantly diminish their accuracy for studying VIC
activation or mimicking healthy valve conditions. To address
this signiﬁcant limitation, recent work by Latif et al identiﬁed
a ﬁbroblast media formulation (FIB) capable of dedifferenti-
ating aVICs and maintaining a qVIC phenotype in human VICs
on TCPS.11 Speciﬁcally, the FIB formulation induced a
decrease in proliferation and contraction, ﬁbroblastlike mor-
phology, and a reduction in the expression of myoﬁbroblastic
proteins compared with culture in standard media.
Porcine hearts, however, remain the most common source
of VICs for researchers,12 and porcine VICs are more prone to
spontaneous in vitro activation than human VICs; thus,
additional treatments beyond the FIB formulation may prove
necessary to achieve quiescence in porcine VICs. Moreover, it
has not been established how the use of qVIC cultures may be
implemented in the setting of a standard experiment to study
pathological stimuli. In the current work, we devised an
accessible method to reliably generate quiescent populations
of porcine VICs in 2-dimensional (2-D) in vitro culture.
Furthermore, we use these qVIC populations to study
phenotype changes following treatment with a known patho-
logical stimulus, transforming growth factor b1 (TGF-b1), and
contrast this against ﬁndings obtained using VICs raised in
standard culture methods, thereby demonstrating the efﬁcacy
of using the qVIC culture method to study VIC pathobiology.
Materials and Methods
VIC Isolation, Culture, and TGF-b Treatment
Aortic valve leaﬂets were excised from male porcine hearts,
and VICs were immediately isolated via collagenase digestion,
as described previously.11,13 The resulting passage 0 VICs
were seeded and expanded on TCPS in low-glucose DMEM
(Sigma-Aldrich) supplemented with 10% heat-inactivated FCS
(Sigma-Aldrich), 150 U/mL penicillin/streptomycin (Sigma-
Aldrich), and 2 mmol/L L-glutamine (Sigma-Aldrich). At
4 days after isolation, VICs were examined via immunocyto-
chemistry and ﬂow cytometry for expression of myoﬁbrob-
lastic markers. By 4 to 6 days after isolation, VICs had
reached 90% conﬂuence and were passaged and divided
into 3 different culture conditions: (1) Control was VICs on
TCPS cultured in standard growth medium, (2) FIB was VICs
on TCPS cultured in FIB media (low-glucose DMEM, 2% heat-
inactivated FCS, 5.25 lg/mL insulin, 10 ng/mL ﬁbroblast
growth factor 2 [FGF-2; PeproTech], 150 U/mL penicillin/
streptomycin, 2 mmol/L L-glutamine), and (3) FIB-Coll was
VICs cultured in FIB media on collagen I–coated TCPS (2 lg/
cm2; Advanced BioMatrix).14 This time point is described as
day 0 throughout this study, with notations of days 4, 9, and
14 referring to the time elapsed since day 0 seeding into
control, FIB, and FIB-Coll conditions. Day 0, passage 1 VICs
were either plated at a 1:10 ratio in TCPS petri dishes or
seeded in 24-well plates at a density of 10 000 cells/cm2 for
phenotypic analysis. This passaging and seeding sequence
was repeated 2 more times, with full refeeding of media every
48 hours. VIC phenotype was analyzed on days 4, 9, and 14
following the initial switch to the FIB formulation. These time
points were selected to align with points at which VICs are
usually passaged for experiment seeding.
To assess the response of VICs to a known disease
stimulus, VICs cultured for 9 days in control, FIB, or FIB-Coll
conditions were seeded at 10 000 cells/cm2 on TCPS and
re-fed with reduced-serum media containing 2% FBS supple-
mented with 0.25 or 1 ng/mL TGF-b1 (PeproTech) 24 hours
after seeding (day 10). VICs were re-fed and treated again
with TGF-b1 48 hours later. VIC phenotype was analyzed on
day 14.
Flow Cytometry and Immunocytochemistry for
Myoﬁbroblastic Markers
The protein expression levels of multiple markers associated
with a myoﬁbroblastic phenotype were assessed via ﬂow
cytometry. For this purpose, VICs (19105) were resuspended in
100 lL of PBS and incubated for 30 minutes on ice with an
unconjugated mouse monoclonal antibody against a-smooth
muscle actin (aSMA; Dako), calponin (Dako), vimentin (Dako),
or vinculin (Millipore) or a rabbit polyclonal antibody against
smooth muscle protein 22-a (SM22; Abcam). Excess primary
antibody was removed by washing in PBS before addition of
ﬂuorescein isothiocyanate–conjugated secondary antibody
(Dako) for 30 minutes on ice. Unbound antibody was removed
in 2washes, and cells were ﬁxed in 150 lL 0.05% formaldehyde
(BDH) before 10 000 events were acquired on an EPICS XL ﬂow
cytometer (Beckman Coulter). Results were expressed as the
percentage of cells staining positively above the control level
(2%), which was derived using cells with no primary antibody
staining or an isotype-matched antibody control, and the mean
ﬂuorescence intensity for each condition was recorded.
Cells were also stained via immunocytochemistry for these
markers to visualize their expression. VICs seeded on
coverslips were washed 2 times with PBS and ﬁxed in 3.7%
formaldehyde solution (Sigma-Aldrich) for 10 minutes. The
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ﬁxative solution was removed by rinsing 3 times with PBS–1%
Tween 20 (PBS-T; Merck). Cells were permeabilized with
Triton X-100 (0.5% vol/vol in PBS-T; Sigma-Aldrich) for
3 minutes, washed 3 times with PBS-T, and blocked for
30 minutes with bovine serum albumin (BSA, 3% wt/vol;
Roche). Directly after blocking, cells were incubated with the
primary antibodies (in 1.5% w/v BSA) at room temperature for
90 minutes. Primary antibodies used were aSMA (Dako),
vimentin (Dako), SM22 (Abcam), and calponin (Dako).
Following washing with PBS-T, samples were incubated with
secondary antibodies labeled with Alexa Fluor 555 or Alexa
Fluor 488 in PBS-T for 60 minutes at room temperature.
Coverslips were mounted on glass slides in DAPI
(40,6-diamidino-2-phenylindole) Fluoromount-G (South-
ernBiotech), which stained the cell nuclei, and imaged on an
Axiovert200M ﬂuorescent microscope (Zeiss).
VIC phenotype was also assessed in freshly harvested
porcine aortic valve leaﬂets. Within 2 hours of slaughter,
leaﬂets were ﬁxed in formalin and then embedded in parafﬁn
and sectioned into 6-lm slices. Sections were deparafﬁnized,
and antigen retrieval was performed in citric acid buffer
(Vector Laboratories) for 2 hours at 80°C. Samples were
incubated overnight in 3% goat serum in PBS followed by
1-hour incubation with mouse anti-aSMA (1:250, monoclonal,
clone 1A4; Sigma-Aldrich) diluted in 1% goat serum and
ﬂuorescent labeling with goat antimouse Alexa Fluor 488
(1:500; Invitrogen) for 1 hour. Samples were counterstained
with DAPI (1:1000; Sigma-Aldrich) for 5 minutes and imaged
using an Olympus IX51 microscope.
Analysis of Cell Morphology
To visualize cell morphology, actin ﬁlaments in VIC cultures
were stained using a Phalloidin-Atto 488 ﬂuorescent label
(Sigma-Aldrich). Cells were ﬁxed with 3.7% formaldehyde
(Sigma-Aldrich) for 10 minutes, permeabilized with 0.05%
Triton X-100 (Sigma-Aldrich) for 3 minutes, and rinsed with
PBS-T prior to incubation with the Phalloidin-Atto 488
ﬂuorescent label for 60 minutes at room temperature.
Coverslips were mounted and stained for cell nuclei with
DAPI Fluoromount-G. Cells were imaged with an Axiovert
200M ﬂuorescent microscope. ImageJ software (National
Institutes of Health) was used to calculate the length, width,
and area of each cell (30–100 cells per condition, 5 different
donor hearts). Aspect ratio was calculated by dividing the
width by the length of each cell (40–70 cells per condition, 5
different donor hearts).
Quantiﬁcation of Proliferation and Apoptosis
Cell proliferation was measured using the Click-iT EdU Alexa
Fluor 488 Imaging Kit (Invitrogen). Brieﬂy, VICs were
incubated with EdU for 8 hours, followed by ﬁxation, perme-
abilization, and labeling with Alexa Fluor 488 via a click
reaction, as described by the manufacturer instructions.
Samples were counterstained with DAPI, and ﬂuorescent
images were captured using an Olympus IX51 microscope.
Cells stained positively for EdU were counted using ImageJ
software and normalized to the total number of cells indicated
by DAPI staining to obtain the percentage of proliferating
cells.
Apoptosis was evaluated with the SensoLyte Homoge-
neous AFC Caspase 3/7 Assay Kit (AnaSpec). This assay
relies on the cleavage of a ﬂuorescent caspase 3/7 substrate
to yield a quantitative measure of relative apoptotic activity
across conditions. Fluorescence readings were obtained using
a Tecan Inﬁnite M1000 plate reader and divided by the
average total number of cells per well in each condition, as
quantiﬁed by DAPI staining. The apoptosis levels were then
normalized to the average of the readings from the control
condition at each time point. In the TGF-b experiments,
apoptosis levels were normalized to the average of the
readings from the 0-ng/mL treatment for each corresponding
condition.
Quantiﬁcation of Myoﬁbroblastic Gene
Expression via Quantitative Reverse
Transcription–Polymerase Chain Reaction
Quantitative reverse transcription–polymerase chain reac-
tion was used to analyze the gene expression levels of
myoﬁbroblastic markers (aSMA [ACTA2], calponin [CNN2],
and smooth muscle protein 22-a [SM22]) and extracellular
matrix proteins (ﬁbronectin [FN] and collagen type I
[COL1A1]) associated with the aVIC phenotype. Markers
associated with an osteoblastic VIC phenotype (alkaline
phosphatase [ALP] and osteocalcin [OCN]) were also
analyzed. VIC RNA was isolated using an RNEasy Mini
Kit (Qiagen), and RNA was reversed transcribed using a
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Quantitative reverse transcription–polymerase
chain reaction was performed with TaqMan Gene Expres-
sion Assays (Applied Biosystems). Analysis of data from
days 4, 9, and 14 was performed using the comparative
CT (DDCT) method, in which the data for each time point
were ﬁrst normalized to 2 endogenous controls (GAPDH
and ACTB) and then to the control condition. To allow
comparison across all conditions, analysis of the TGF-b
experiment was performed using the relative standard
curve CT method, in which a set of standards was
generated for each gene from control samples, with
normalization to endogenous expression of GAPDH. Data
were expressed as fold change relative to 0-ng/mL TGF-b
treatment for each condition.
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Analysis of Fibronectin Deposition via In Situ
ELISA
Fibronectin deposition was assayed by semiquantitative
immunocytochemical detection. Cells were ﬁxed in 10%
neutral buffered formalin (Sigma-Aldrich), endogenous perox-
idase activity was quenched with 0.3% hydrogen peroxide in
methanol for 1 hour, and samples were blocked overnight in
3% goat serum. Samples were then incubated with mono-
clonal rabbit antiﬁbronectin antibody (polyclonal, 0.4 lg/mL;
Santa Cruz Biotechnology) for 2 hours, followed by a series of
washes with 1X PBS and labeling with a horseradish
peroxidase–linked goat antirabbit secondary antibody (poly-
clonal, 0.5 lg/mL; Alpha Diagnostic International) for
40 minutes. After washing, samples were incubated in 1-Step
Turbo-TMB ELISA substrate solution (Thermo Fisher Scien-
tiﬁc), and the reaction stopped after 5 minutes through the
addition of 2 N sulfuric acid (Thermo Fisher Scientiﬁc). Color
development was proportional to ﬁbronectin content and
measured with a Tecan Inﬁnite M1000 plate reader. Back-
ground signal was determined by following the same proce-
dure without incubating in primary antibody solution. This
background absorbance was subtracted from the samples for
the respective culture condition. Corrected absorbance values
were normalized to total cell number determined by DAPI
staining and expressed as a fold change over the control
condition at each time point.
Quantiﬁcation of Inﬂammatory Cytokine
Production
The production of inﬂammatory cytokines by VICs cultured in
control and FIB-Coll conditions was evaluated via ELISAs for
interleukin 6 (IL-6) and IL-8. VICs were cultured for 9 days in
control or FIB-Coll conditions and then seeded at
10 000 cells/cm2 on TCPS and re-fed with reduced-serum
media containing 2% FBS. After 5 days of culture, the
concentrations of IL-6 and IL-8 in VIC culture supernatants
were quantiﬁed via ELISA, according to the manufacturer’s
instructions (R&D Systems). A PicoGreen assay (Invitrogen)
was used to quantify DNA in the cell culture lysates collected
from the aforementioned samples, and inﬂammatory cytokine
concentrations were normalized to DNA amount.
Statistical Analysis
Each experiment was conducted using 6 to 8 individual
isolates, for which isolate refers to the VICs isolated from an
individual heart. A total of 29 different hearts were used
across the entire study. Data are presented as meanSD, and
statistical analyses were performed using GraphPad Prism
software. Experimental groups were compared with each
other using 2-way ANOVA, with repeated measures for the
time course experiments, in conjunction with the Tukey
honestly signiﬁcant difference post-test. Data that were not
normally distributed were analyzed using a Kruskal–Wallis
1-way ANOVA followed by a Dunn post hoc test. P values
≤0.01 were considered statistically signiﬁcant.
Results
Porcine VICs Exhibit Myoﬁbroblastic Behavior
Shortly After Isolation
The baseline phenotype of porcine VICs cultured in control (ie,
normal growth medium) conditions was evaluated via ﬂow
cytometry 4 days after isolation, at passage 0. Even at this
early time point, a high percentage of VICs expressed the
following myoﬁbroblastic markers: vimentin (88%), aSMA
(79%), SM22 (41%), and calponin (19%) (Table). These results
were conﬁrmed visually through immunocytochemistry (Fig-
ure 1). In contrast, most VICs found in healthy porcine aortic
valves exhibit a quiescent phenotype (Figure S1). Standard
culture methods led to robust and quick transformation of
qVICs into an aVIC phenotype.
VICs Cultured in FIB or FIB-Coll Conditions Do Not
Exhibit Myoﬁbroblastic Morphology
The morphology of VICs cultured in control, FIB, and FIB-Coll
conditions was evaluated, as myoﬁbroblastic differentiation of
cells is typically accompanied by a large increase in cell area
and an evenly spread morphology. Staining with phalloidin
resulted in the visualization of clear differences in cell shape
at all time points between VICs cultured in FIB or FIB-Coll
conditions compared with control VICs (Figure 2A). On day 0,
which corresponds to 4 days after the initial harvest of VICs
from intact leaﬂets, VICs already demonstrated the spread,
ﬂattened appearance that is characteristic of myoﬁbroblasts.
At subsequent time points, control VICs continued to exhibit
this myoﬁbroblastic morphology, whereas VICs cultured in FIB
or FIB-Coll exhibited a thinner, spindled shape with long
extensions. Quantiﬁcation of cell shape and aspect ratio
conﬁrmed these observations and revealed that, as early as
Table. Mean Percentage of Passage 0 Valvular Interstitial
Cells Positive for Myoﬁbroblastic Markers
Marker Percentage (SD)
a-Smooth muscle actin 79.4 (5.1)
Calponin 18.6 (1.9)
Smooth muscle protein 22-a 41.4 (23.1)
Vimentin 88.2 (4.4)
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4 days after initiation of FIB or FIB-Coll treatment, VICs
exhibited a 2-fold decrease in area and aspect ratio (Figure 2B
and 2C). No signiﬁcant differences were noted between FIB
and FIB-Coll conditions. These trends were sustained through-
out the course of the study.
FIB-Coll Decreases VIC Proliferation and
Apoptosis
Cell quiescence is generally associated with low rates of
proliferation and apoptosis.15,16 These behaviors were
assessed in control, FIB, and FIB-Coll conditions at time
points of 4, 9, and 14 days following the transition to FIB or
FIB-Coll conditions. At all time points, VICs cultured in FIB
medium exhibited signiﬁcantly lower proliferation than those
cultured in control medium (Figure 3A). At day 4, no
additional change in proliferation was conferred by the FIB-
Coll condition relative to FIB alone. However, signiﬁcant
differences between FIB and FIB-Coll emerged by day 9, at
which point VIC proliferation in FIB-Coll was signiﬁcantly lower
than that in FIB (18% versus 28%). At day 14, this difference
was even more pronounced (11% for Fib-Coll versus 32% for
FIB).
VICs exhibited lower caspase 3/7 activity, indicative of
lower levels of apoptosis, in FIB medium compared with
control medium at day 4 (Figure 3B). At both days 9 and 14,
however, apoptosis levels in FIB medium were equivalent to
those observed in the control condition. In contrast, VICs
cultured in FIB-Coll exhibited signiﬁcantly lower apoptosis
compared with control media at all time points.
Myoﬁbroblastic Marker Expression Is Reduced by
FIB and FIB-Coll
The gene expression of proteins associated with VIC
activation and myoﬁbroblastic differentiation was assessed
via quantitative reverse transcription–polymerase chain
reaction. At all time points, culture in FIB or FIB-Coll
conditions led to signiﬁcantly lower expression of ACTA2,
SM22, and CNN2 (Figure 4A–4C). At day 4, a 3-fold
decrease in ACTA2 and SM22 mRNA levels was observed in
FIB and FIB-Coll relative to control medium. Meanwhile, VIC
culture in FIB-Coll was signiﬁcantly more effective than FIB
in decreasing the expression of CNN2. At days 9 and 14,
both FIB and FIB-Coll exhibited similar abilities to decrease
expression of myoﬁbroblastic markers, yielding a 4-fold
decrease in ACTA2, SM22, and CNN2 relative to the
control.
To conﬁrm these ﬁndings at the protein level, myoﬁbrob-
lastic marker expression was analyzed via ﬂow cytometry
(Figure 4D–4F, Figure S1). At day 4, no statistically signif-
icant differences in aSMA, calponin, or SM22 mean ﬂuores-
cence intensity were found across conditions. At day 9, VICs
exhibited a 2-fold decrease in aSMA expression in both FIB
and FIB-Coll conditions compared with the control, ultimately
yielding a 5-fold decrease by day 14 (Figure 4D). Similarly,
both FIB and FIB-Coll led to a decrease in calponin
expression levels by day 14 (Figure 4E). SM22 levels were
signiﬁcantly reduced in FIB compared with the control at day
14, whereas FIB-Coll appeared to have no effect on the
ﬂuorescence intensity of this marker at any time point. The
percentage of VICs positive for aSMA, calponin, and SM22
also decreased after day 9 and beyond in FIB and FIB-Coll
(Figure S2). Because the reported mean ﬂuorescence
intensity refers to the expression levels only in the cells
that stained positively, immunocytochemistry was also
performed to better characterize VIC phenotype. This
analysis revealed stark differences in myoﬁbroblastic protein
expression between the control and FIB or FIB-Coll condi-
tions (Figure 4G, Figure S3) that conﬁrmed the polymerase
chain reaction and ﬂow cytometry ﬁndings. As early as day 4,
a decrease in staining for aSMA, calponin, and SM22 in VICs
cultured in FIB and FIB-Coll was observed. This decrease was
sustained at days 9 and 14.
Figure 1. Immunohistochemical staining for activated VIC markers in passage 0 VIC cultures. VICs expressed vimentin and the
myoﬁbroblastic markers aSMA, calponin, and SM22 after culture in control conditions. Detected proteins are stained red, and nuclei are stained
blue. Scale bar represents 100 lm. aSMA indicates a-smooth muscle actin; SM22, smooth muscle protein 22-a; VIC, valvular interstitial cell.
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ECM Production Is Reduced by FIB and FIB-Coll
A myoﬁbroblastic phenotype is typically associated with
increased ECM production. Results shown in Figure 5
demonstrate that collagen gene expression by VICs cultured
in FIB or FIB-Coll was lower at all time points compared with
the control condition (Figure 5A). On day 4, however, culture
in FIB-Coll was more effective than FIB alone in suppressing
COL1A1 expression, yielding a 0.2 fold change in expression
relative to control, compared with 0.7 for FIB. By day 9, there
was no longer a signiﬁcant difference in the expression levels
between the FIB and FIB-Coll conditions. This trend was
maintained at day 14, at which point both FIB and FIB-Coll had
decreased COL1A1 expression by 5-fold relative to the
control. Protein levels of collagen were not assessed because
of interference created by the collagen coating in the FIB-Coll
condition.
Figure 2. VICs cultured in FIB or FIB-Coll conditions exhibit a more elongated and spindled morphology compared with control VICs.
A, Staining for phalloidin (red), nuclei are counterstained blue. Scale bar represents 100 lm. Quantiﬁcation of (B) cell shape and (C) aspect ratio
for VICs cultured in control, FIB, or FIB-Coll conditions. *P<0.01 compared with control VICs at the same time point. ^P<0.01 compared with day
4 VICs cultured in the same condition. n=6. FIB indicates ﬁbroblast media formulation; FIB-Coll, ﬁbroblast media formulation with culture on
collagen coatings; VIC, valvular interstitial cell.
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There was no difference in FN gene expression (Figure 5B)
or protein production (Figure 5C) between control and FIB
medium after 4 days in culture. In contrast, VICs cultured in
FIB-Coll exhibited a signiﬁcant decrease in FN gene expres-
sion and ﬁbronectin deposition at that same time point. By
day 9, both FIB and FIB-Coll conditions yielded a statistically
signiﬁcant reduction in FN gene expression and protein
deposition compared with the control. At day 14, the
difference between either of the FIB treatments and the
control was >2-fold for both gene expression and protein
deposition.
qVICs Generated via Culture in FIB-Coll Exhibit
Increased Sensitivity to TGF-b1 Treatment
We next examined whether the qVICs generated by FIB or FIB-
Coll treatment exhibited differential responsiveness to a
known stimulus of myoﬁbroblastic differentiation, TGF-b1,
compared with the aVICs generated via standard culture
conditions. VICs were cultured in control, FIB, or FIB-Coll
conditions until the day 9 time point described in previous
sections. At this point, instead of continuing in FIB or FIB-Coll
conditions, all VICs were seeded on TCPS and treated with 0,
0.25, or 1 ng/mL TGF-b1 in reduced-serum media for 5 days.
Treatment with TGF-b1 had no effect on cell morphology in
VICs that had been raised in control or FIB conditions
(Figure 6A–6C). In contrast, qVICs generated via FIB-Coll
culture exhibited an increase in aspect ratio following
treatment with 1 ng/mL TGF-b1. Similarly, the proliferation
of VICs generated by culture in control or FIB conditions was
unaffected by TGF-b1 treatment (Figure 6D), whereas both
TGF-b1 doses signiﬁcantly increased the proliferation of qVICs
raised in FIB-Coll culture. Combined with the morphology
data, these ﬁndings suggested that qVICs generated via
FIB-Coll culture underwent myoﬁboblastic differentiation on
TGF-b1 treatment. Although TGF-b1 induced apoptosis in
VICs raised in all 3 conditions, the most dramatic increase in
VIC apoptosis relative to no treatment was observed in qVICs
generated via FIB-Coll culture.
Quantiﬁcation of gene and protein expression levels of
myoﬁbroblastic markers (Figure 7A–7C) yielded ﬁndings that
were consistent with our data on cell shape and proliferation.
Neither dose of TGF-b1 was able to induce myoﬁbroblastic
differentiation of control VICs, as indicated by unchanged
ACTA2 and SM22 expression compared with untreated
cultures. Meanwhile, qVICs generated via FIB culture exhibited
some myoﬁbroblastic characteristics in response to TGF-b1
treatment; although ACTA2 expression remained unchanged
at both TGF-b1 doses, the higher dose (1 ng/mL) of TGF-b1
increased the expression of SM22. Consistent with the results
for morphology, proliferation, and apoptosis, qVICs raised in
FIB-Coll culture exhibited the greatest sensitivity to TGF-b1-
induced myoﬁbroblastic differentiation. Treatment of these
qVICs with only 0.25 ng/mL TGF-b1 increased expression of
ACTA2 and SM22 by >5- and >4-fold, respectively, compared
with untreated qVICs. These observations were also reﬂected
by immunoﬂuorescent staining for aSMA and SM22 (Fig-
ure 7C), with which qVICs generated in FIB-Coll culture
displayed a noticeable increase in SM22 on TGF-b1 treat-
ment, whereas VICs from control or FIB conditions appeared
relatively unchanged. The increase in aSMA protein in TGF-b1-
treated qVICs from FIB-Coll culture was less prominent,
perhaps because aSMA is typically produced at a slightly later
time than SM22 during myoﬁbroblastic differentiation.17
TGF-b1 is known as a potent stimulus of ECM production in
many cell types; this was also the case for all conditions in the
current study (Figure 7D–7F). Control VICs exhibited an
increase in COL1A1 and FN gene expression after treatment
with the higher dose (1 ng/mL) of TGF-b1. Meanwhile, VICs
conditioned through FIB or FIB-Coll were responsive to both
Figure 3. VIC proliferation and apoptosis decrease after culture in FIB-Coll. A, Quantiﬁcation of the
percentage of proliferating cells after 8 hours of incubation with EdU. B, Evaluation of apoptosis levels
through a caspase 3/7 activity assay. *P<0.01 compared with control VICs at the same time point. ^P<0.01
compared with day 4 VICs cultured in the same condition. #P<0.01 for comparisons indicated on graph.
n=6 to 8. FIB indicates ﬁbroblast media formulation; FIB-Coll, ﬁbroblast media formulation with culture on
collagen coatings; VIC, valvular interstitial cell.
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the low and high doses of TGF-b1, resulting in signiﬁcantly
increased COL1A1 and FN mRNA levels compared with
untreated cells. Analysis of ﬁbronectin protein production
showed signiﬁcant increases in ﬁbronectin production by VICs
raised in control or FIB-Coll conditions.
Finally, it is important to note that VICs generated via FIB or
FIB-Coll culture and not treated with TGF-b1 maintained a qVIC
phenotype throughout the course of the 5-day experiment, even
in the absence of insulin, FGF-2, and a collagen coating. These
VICs continued to exhibit smaller cell area (Figure 6B),
proliferated at lower rates (Figure 6D), expressed lower levels
of myoﬁbroblastic markers (Figure 7C, Figure S4A and S4B),
and produced less ECM (Figure S4C and S4D) compared with
control VICs raised in standard growth medium.
Figure 4. Expression of myoﬁbroblastic markers decreases dramatically after culture in FIB and FIB-Coll. A through C, Gene expression
analysis of (A) ACTA2, (B) CNN2, and (C) SM22 after 4, 9, and 14 days of culture in control, FIB, or FIB-Coll conditions. D through F, Evaluation of
protein expression for the same markers: (D) aSMA, (E) calponin, and (F) SM22. MFI levels were obtained through ﬂow cytometry. G,
Immunostaining for myoﬁbroblastic markers. Scale bar represents 100 lm. *P<0.01 compared with control VICs at the same time point.
^P<0.01 compared with day 4 VICs cultured in the same condition. #P<0.01 for comparison indicated on graph. n=6. aSMA indicates a-smooth
muscle actin; FIB, ﬁbroblast media formulation; FIB-Coll, ﬁbroblast media formulation with culture on collagen coatings; MFI, mean ﬂuorescence
intensity; SM22, smooth muscle protein 22-a; VIC, valvular interstitial cell.
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The spontaneous activation of VICs in standard in vitro culture
on TCPS is a major limiting factor in the study of healthy valve
biology and calciﬁc aortic valve disease (CAVD). Previously, a
media formulation (FIB) capable of deactivating VICs had been
reported; however, this formulation had been tested only on
cells isolated from human valves,11 which experience less
robust myoﬁbroblastic activation in culture. Moreover, the
utility of these cells in studying VIC response to pathological
stimuli has not been demonstrated. In the current study,
culture of porcine VICs on TCPS in FIB media signiﬁcantly
reduced several markers of VIC activation, including prolifer-
ation, apoptosis, aSMA expression, and matrix production,
relative to standard growth medium. A combination of FIB
with culture on collagen coatings (FIB-Coll) achieved similar
results and an even greater reduction of proliferation,
apoptosis, and matrix production compared with FIB media
alone. To our knowledge, this is the ﬁrst time that such robust
VIC deactivation has been achieved in 2-dimensional culture.
Moreover, VICs generated via FIB-Coll culture exhibited
increased responsiveness to TGF-b1, a known inducer of
myoﬁbroblastic activation, compared with either standard VIC
cultures or those treated with FIB media alone. This method of
maintaining a porcine qVIC phenotype provides a valuable
platform for mimicking healthy valve behavior and for studying
disease stimuli in aortic valve disease.
We demonstrated that a large percentage of porcine
VICs cultured under standard conditions express myoﬁbrob-
lastic markers shortly after isolation, prior to passaging.
This VIC activation could be reversed by culture in FIB or
FIB-Coll conditions, where characteristics of a quiescent
phenotype emerged after only 4 days in culture, including
changes in cell shape and a decrease in proliferation,
apoptosis, myoﬁbroblastic gene expression, and ECM pro-
duction. By day 9, the reduction in all of those features had
become more pronounced, and the effect on myoﬁbroblas-
tic marker expression could be detected at the protein
level. At day 14, no further effect of the FIB or FIB-Coll
treatment on VIC phenotype was observed for most metrics
analyzed. Perhaps even more strikingly, the quiescent
features induced by FIB and FIB-Coll were sustained even
after 5 days in culture without the full FIB formulation or a
collagen coating (Figure S4). Because the myoﬁbroblast
phenotype may be transient in a diseased valve and segue
into inﬂammatory activity and/or osteogenic differentiation,
markers for these further downstream phenotypes were
also evaluated; both the production of inﬂammatory cytoki-
nes and the osteogenic marker alkaline phosphatase were
found to be signiﬁcantly decreased in FIB and FIB-Coll
cultures relative to the control (Figure S5). Consequently,
we developed a robust method to efﬁciently generate qVICs
in <2 weeks that can then be used for further experiments
without signiﬁcant phenotypic drift.
This dramatic change in VIC phenotype warrants closer
examination of the culture conditions selected for this study.
Latif et al published a full rationale for the selection of the
cocktail present in FIB media.11 Brieﬂy, supplementation with
2% FBS was selected over the traditional 10% concentration to
reduce the amount of growth factors present in the medium.
In addition, insulin and FGF-2 were selected for their reported
ability to regulate growth18 and decrease VIC aSMA expres-
sion,19 respectively. Meanwhile, collagen has been previously
associated with decreased VIC pathology in both 2D and 3D
studies.14,20,21 Our experiments found that collagen coating
alone can decrease the expression of contractile proteins but
signiﬁcantly increases VIC proliferation and thus is unable to
yield a qVIC phenotype (Figure S6); others have similarly
found that collagen is not sufﬁcient to yield qVIC cultures.11,14
We hypothesized, however, that the combination of a collagen
coating with soluble factors (ie, FIB-Coll condition) might
provide additional deactivation cues. This hypothesis was
Figure 5. Extracellular matrix production decreases after culture in FIB and FIB-Coll. A, COL1A1 gene expression was evaluated after 4, 9, and
14 days of culture in control, FIB, or FIB-Coll conditions. Fibronectin (B) gene and (C) protein expression were also assessed. *P<0.01 compared
with control VICs at the same time point. ^P<0.01 compared with day 4 VICs cultured in the same condition. #P<0.01 for comparison indicated
on graph. n=6. FIB indicates ﬁbroblast media formulation; FIB-Coll, ﬁbroblast media formulation with culture on collagen coatings; VIC, valvular
interstitial cell.
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conﬁrmed by the data: Although the FIB formulation alone
was sufﬁcient to generate signiﬁcant reductions in myoﬁ-
broblast markers, culture in FIB-Coll achieved the same
results, sometimes sooner (4 versus 9 days for ECM produc-
tion) and at other times more dramatically (eg, proliferation
and apoptosis), compared with FIB alone. Moreover, qVICs
generated via FIB-Coll culture exhibited markedly higher
sensitivity to TGF-b1 treatment. Consistent with previous
work,14,20–22 these ﬁndings point to an important role for
collagen in sustaining healthy VIC function and valve home-
ostasis. Further study is needed to elucidate the mechanisms
by which these soluble and insoluble cues are able to
Figure 6. TGF-b1 induces changes in cell morphology, proliferation, and apoptosis in VICs generated via
FIB-Coll culture. VICs raised in control, FIB, or FIB-Coll culture were treated with 0, 0.25, or 1 ng/mL TGF-
b1 for 5 days on tissue culture polystyrene. A, Staining for phalloidin (green), nuclei are counterstained
blue. Scale bar represents 100 lm. Quantiﬁcation of (B) cell shape, (C) aspect ratio, (D) proliferation, and
(E) apoptosis. *P<0.01 compared with 0 ng/mL in the same condition (control, FIB, or FIB-Coll). ^P<0.01
compared with control VICs treated with the same amount of TGF-b1. n=6 to 8. FIB indicates ﬁbroblast
media formulation; FIB-Coll, ﬁbroblast media formulation with culture on collagen coatings; TGF-b1,
transforming growth factor b1; VIC, valvular interstitial cell.
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modulate VIC phenotype; a preliminary investigation of
vinculin expression suggests that focal adhesion-related
pathways may be involved (Figure S6C).
Although this is not the ﬁrst report of successful deacti-
vation of porcine VICs in in vitro culture, it is the only method
described for 2D culture and thus is easily implemented for
Figure 7. VICs raised in FIB-Coll culture respond more strongly to TGF-b1 treatment than VICs raised in FIB and control culture.
Myoﬁbroblastic marker and ECM expression were also analyzed in response to TGF-b1 treatment. The extent of VIC activation was evaluated
through gene expression analysis of (A) ACTA2 and (B) SM22 and (C) immunoﬂuorescent staining for aSMA and SM22. Red indicates positive
staining for each marker; nuclei are counterstained blue. Scale bar represents 100 lm. ECM production was assessed through quantitative
reverse transcriptase–polymerase chain reaction for (D) COL1A1 and (E) FN, as well as an in situ ELISA for (F) ﬁbronectin protein deposition.
*P<0.01 compared with 0 ng/mL in the same condition (control, FIB, or FIB-Coll). #P<0.01 for comparison indicated on graph. n=6. aSMA
indicates a-smooth muscle actin; ECM, extracellular matrix; FIB, ﬁbroblast media formulation; FIB-Coll, ﬁbroblast media formulation with culture
on collagen coatings; SM22, smooth muscle protein 22-a; TGF-b1, transforming growth factor b1; VIC, valvular interstitial cell.
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large-scale VIC expansion and subsequent seeding for exper-
iments. Other approaches for reducing aSMA expression have
involved 3D VIC culture in soft hydrogels.10,23–25 Interestingly,
VIC encapsulation in synthetic hydrogels decorated with
peptides derived from collagen I led to the lowest percentage
of aSMA-positive VICs compared with ﬁbronectin- and elastin-
derived peptides.23 In many of these cases, the ability to
induce the quiescent phenotype has been hypothesized to
depend on the soft mechanical properties of these materi-
als.26,27 Within our system, the presence of both soluble
(insulin and FGF-2) and insoluble (collagen) biochemical cues
appeared to be sufﬁcient to overcome the effect of culture on
stiff TCPS substrates. Although the aforementioned 3D
systems provide elegant platforms for investigating VIC
behavior in response to microenvironmental stimuli, they
are not intended as a means of regular generation of qVIC
populations for subsequent seeding and experimentation.
Most laboratories do not possess the expertise to synthesize
the biomaterials necessary for these systems, and the costs
associated with these methods are too high for the contin-
uous generation of qVICs. Furthermore, the difﬁculties
associated with isolating cells from 3D matrices without
incurring cellular damage limit the utility of VICs cultured in
this manner for follow-up experiments. In contrast, the FIB-
Coll method presented in this paper is easy to use and
inexpensive; only small quantities of FGF-2 and collagen are
necessary to achieve the desired effect. In addition, it can
easily be scaled up or down according to the desired
application. Any laboratory already performing valve-related
research could readily adopt this approach. The ability of the
geographically diverse author team to generate reproducible,
consistent results in experiments performed in 3 different
countries and using independent sources of pig hearts also
serves as a testament to the reliability and robustness of the
FIB-Coll approach.
As discussed previously, although aVICs are rare in
healthy valves (Figure S1), existing in vitro studies have been
performed predominantly on aVICs and, therefore, may not
accurately represent the VIC response to pathological stimuli
in the native valve environment. Our hypothesis that qVICs
would be more sensitive to a myoﬁbroblastic stimulus was
borne out by administration of TGF-b1 to VICs raised in FIB,
FIB-Coll, or control conditions. Increased levels of TGF-b1
are found in CAVD,28 and this molecule is widely studied as
an inducer of VIC pathology to better understand its role in
disease progression.28–30 Our control condition represents
the standard approach that is used to grow VICs, including
those used in studies involving TGF-b treatment29–31;
however, these cells are already predominantly aVICs and
remain unaltered with respect to morphology, proliferation,
and myoﬁbroblastic gene expression when treated with TGF-
b, thereby illustrating the serious problem in using VICs
raised in standard growth medium to study VIC pathology.
Meanwhile, VICs raised in FIB-Coll conditions were highly
sensitive to TGF-b1, exhibiting changes in cell aspect ratio
and large increases in cell proliferation, apoptosis, myoﬁ-
broblastic gene and protein expression, and ECM production.
These responses were elicited by 0.25- and 1-ng/mL
dosages of TGF-b1; there do not appear to be any previous
reports of a TGF-b1 dose as low as 0.25 ng/mL being
capable of inducing VIC activation.14,29,31–35 In contrast to
VICs grown in standard culture conditions, which exhibited a
diminished response to this disease stimulus, qVICs gener-
ated via FIB-Coll culture required only a small perturbation
with TGF-b1 to elicit dysfunctional behavior. It is likely that
the control VICs would have responded to much higher
doses of TGF-b1 (eg, 5 ng/mL),32,36,37 but the physiological
relevance of a majority aVIC population receiving high doses
of TGF-b1 is questionable. Consequently, qVICs generated
via FIB-Coll culture may provide a more accurate model to
elucidate the mechanisms of VIC activation and dysfunction,
which have been elusive because of the lack of a starting
healthy population. The ability to generate qVICs can be
applied to the study of CAVD etiology by enabling the
creation of culture environments that are appropriate for
studying disease onset (ie, predominantly qVICs) or different
stages of disease progression (ie, varying ratios of qVIC:
aVIC, depending on extent of disease). The differential
responsiveness of qVICs and aVICs to TGF-b1 in our study
emphasizes the importance of using the VIC phenotype that
is most appropriately matched to the biological question or
disease stage being investigated.
Conclusions
We developed a facile method to reliably and robustly
generate porcine qVIC cultures, which are intended to mimic
the healthy VIC population in the aortic valve and thus
improve our ability to study pathological stimuli involved in
CAVD. The culture conditions described in this work comple-
ment existing methods to generate osteoblastic VICs,38,39 a
phenotype thought to be responsible for leaﬂet mineralization
in the late stages of CAVD.4 This work has signiﬁcant
implications for the valve research community, as the ability
to generate the VIC phenotypes involved in CAVD progression
(qVICs, aVICs, and osteoblastic VICs) is a critical advance-
ment necessary for deciphering the mechanisms of this
disease. As the ﬁeld continues to develop more complex
platforms for cell culture involving combinations of environ-
mental cues, researchers will need to carefully assess the
correct VIC phenotypes to be used depending on the
pathological event being studied, for example, lipid oxidation
(early in CAVD)40 versus angiogenesis (later in CAVD). The
importance of using the correct VIC phenotype will become
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increasingly important as these models transition from tools
for basic research and discovery to drug testing applications;
for example, multiple studies have reported that statin drugs
elicit differential responses in aVICs versus osteoblastic
VICs.41,42 Careful evaluation not only of the biochemical and
physical cues present in each model but also of the starting
phenotype of the VICs under study will be necessary to mimic
healthy and diseased valve behavior and to reliably predict
biological responses to pharmacological treatments.
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Figure S1. VICs are quiescent in freshly explanted porcine aortic valve leaflets. Immunofluorescent 
staining for αSMA demonstrated the absence of activated VICs in healthy aortic valves. αSMA - green, 
DAPI – blue. Scale bar represents 200 μm.  
  
  
Figure S2. The percentage of VICs positive for myofibroblastic markers decreases after culture in 
FIB or FIB-Coll. Quantification of A) αSMA, B) calponin, and C) SM22 protein expression via flow 
cytometry. *p < 0.05 compared to control VICs at the same timepoint. ^p < 0.05 compared to day 4 VICs 















Figure S3. Myofibroblastic marker expression after 14 days of culture in control, FIB, or FIB-Coll. 











Figure S4. VICs generated via FIB or FIB-Coll culture remained quiescent for 5 days following 
removal of FIB or FIB-Coll conditions. Quantification of myofibroblastic (αSMA and SM22) and ECM 
(Col1A1 and FN) gene expression. *p <0.05 compared to control, ^p <0.05 for indicated comparison. 
  
  
Figure S5. VICs cultured in FIB-Coll conditions exhibited decreased inflammatory cytokine 
production and osteogenic activity relative to control. The inflammatory activity of VICs was 
assessed using ELISAs for A) IL-6 and B) IL-8. The expression of C) alkaline phosphatase (ALP) and D) 
osteocalcin (OCN) genes by VICs in different culture environments was evaluated as a measure of 
osteogenic activity. The “Standard” is a positive control generated by culture of VICs on uncoated tissue 
culture polystyrene and treatment with osteogenic medium (DMEM with 10% FBS, 100 U/mL penicillin, 
100 µg/mL streptomycin, 2 mM L-glutamine, 10 mM β-glycerophosphate, and 50 µg/ml ascorbic acid). * P 
< 0.05 compared to control VICs.  
 
 Figure S6. Culture on collagen alone (Coll) was insufficient to yield a quiescent phenotype. A) VIC 
proliferation on Coll was significantly increased relative to the control and conditions containing FIB media, 
although B) VICs on Coll exhibited decreased expression of contractile proteins relative to the control. * P 
< 0.05 compared to control VICs. ^ P < 0.05 compared to VICs cultured in COLL. C) An initial increase in 
vinculin expression was noted in FIB-COLL conditions at Day 4, but then significantly decreased at later 
time points. *P < 0.05 compared to control VICs at the same time point. ^ P < 0.05 compared to day 4 
VICs cultured in the same condition. 
 
